# AJU Pharm Co., Ltd. clinical trials: 21 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 21 trials with AJU Pharm Co., Ltd. as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by AJU Pharm Co., Ltd.: 21 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/aju-pharm-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 21
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 21 newest of 21, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07901114 | A Bioequivalence and Safety Study of AJU-C719 and C719R in Healthy Adult Volunteers | AJU Pharm Co., Ltd. | Phase 1 | Not yet recruiting | Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901114) |
| October 28, 2026 | NCT07901088 | A Bioequivalence and Safety Study of AJU-B718 and B718R in Healthy Adult Volunteers Under Fasting Conditions | AJU Pharm Co., Ltd. | Phase 1 | Not yet recruiting | Peripheral Arterial Disease | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901088) |
| June 18, 2026 | NCT07655960 | To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C716 and C716R in Healthy Adults | AJU Pharm Co., Ltd. | Phase 1 | Completed | Hypercholesterolemia, Dyslipidemia | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07655960) |
| June 11, 2026 | NCT07643233 | Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fed Conditions | AJU Pharm Co., Ltd. | Phase 1 | Not yet recruiting | Moderate-to-severe Benign Prostatic Hyperplasia (BPH) | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643233) |
| June 11, 2026 | NCT07643220 | Bioequivalence Study of AJU-G721 and G721R in Healthy Adult Volunteers Under Fasting Conditions | AJU Pharm Co., Ltd. | Phase 1 | Completed | Moderate-to-severe Benign Prostatic Hyperplasia (BPH) | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07643220) |
| May 12, 2026 | NCT07581028 | Bioequivalence Study of AJU-C715 and C715R in Healthy Adult Volunteers | AJU Pharm Co., Ltd. | Phase 1 | Completed | Hypercholerolemia, Dyslipidemia | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07581028) |
| November 17, 2025 | NCT07231861 | Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers | AJU Pharm Co., Ltd. | Phase 1 | Completed | Bronchial Asthma, Perennial Allergic Rhinitis | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07231861) |
| November 17, 2025 | NCT07230184 | To Evaluate the Efficacy and Safety of Combination Therapy With B55R1 and B55R2 Compared to B55R1 Monotherapy in Patients With NPDR | AJU Pharm Co., Ltd. | Phase 4 | Completed | Non-Proliferative Diabetic Retinopathy | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07230184) |
| July 1, 2025 | NCT07044765 | A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study | AJU Pharm Co., Ltd. | Phase 1 | Not yet recruiting | Type2 Diabetes Mellitus | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07044765) |
| June 24, 2025 | NCT07034781 | A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults | AJU Pharm Co., Ltd. | Phase 1 | Not yet recruiting | Type2 Diabetes Mellitus | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07034781) |
| April 18, 2025 | NCT06933459 | To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C714 and C714R in Healthy Adults | AJU Pharm Co., Ltd. | Phase 1 | Active not recruiting | Dyslipidemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06933459) |
| April 17, 2025 | NCT06931327 | To Evaluate the Safety and Pharmacokinetic Characteristics of AJU-C711 in Healthy Adults | AJU Pharm Co., Ltd. | Phase 1 | Completed | Hypercholesterolemia | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06931327) |
| May 16, 2024 | NCT06416865 | Efficacy and Safety of AJU-C52 in Essential Hypertension Patients | AJU Pharm Co., Ltd. | Phase 3 | Completed | Essential Hypertension | 193 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06416865) |
| April 3, 2024 | NCT06345014 | The Efficacy and Safety of OM-89 in Patients With Recurrent Chronic Prostatitis/Chronic Pelvic Pain Syndrome | AJU Pharm Co., Ltd. | Phase 4 | Unknown | Chronic Prostatitis With Chronic Pelvic Pain Syndrome, Chronic Prostatitis, Chronic Pelvic Pain Syndrome | 332 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06345014) |
| March 29, 2024 | NCT06337981 | Efficacy and Safety of AJU-S56 in Dry Eye Syndrome Patients | AJU Pharm Co., Ltd. | Phase 2 | Completed | Dry Eye Syndromes | 99 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06337981) |
| March 26, 2024 | NCT06329674 | Efficacy and Safety of AJU-A51 in Type 2 Diabetes Mellitus Patients | AJU Pharm Co., Ltd. | Phase 3 | Completed | Type2 Diabetes | 235 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06329674) |
| March 4, 2024 | NCT06291194 | Efficacy and Safety of AJU-S56 5% in Dry Eye Syndrome Patients | AJU Pharm Co., Ltd. | Phase 3 | Unknown | Dry Eye Syndromes | 396 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06291194) |
| October 14, 2021 | NCT05077475 | A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52L in Healthy Volunteers | AJU Pharm Co., Ltd. | Phase 1 | Unknown | Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05077475) |
| October 14, 2021 | NCT05077462 | A Clinical Trial to Evaluate the Safety and Pharmacokinetics of AJU-C52H in Healthy Volunteers | AJU Pharm Co., Ltd. | Phase 1 | Unknown | Hypertension | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05077462) |
| July 22, 2021 | NCT04972539 | Evaluation of Pharmacokinetics and Safety of AJU-A51 in Healthy Adults | AJU Pharm Co., Ltd. | Phase 1 | Completed | Diabetes Mellitus, Type 2 | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04972539) |
| July 21, 2021 | NCT04970940 | The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2 | AJU Pharm Co., Ltd. | Phase 1 | Completed | T2DM (Type 2 Diabetes Mellitus) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04970940) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 15 |
| Phase 2 | 1 |
| Phase 3 | 3 |
| Phase 4 | 2 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 11 |
| Not yet recruiting | 5 |
| Unknown | 4 |
| Active not recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Dyslipidemias | 3 |
| Hypertension | 3 |
| Dry Eye Syndromes | 2 |
| Hypercholesterolemia | 2 |
| Diabetes Mellitus, Type 2 | 2 |
| Asthma | 1 |
| Rhinitis, Allergic, Perennial | 1 |
| Prostatitis | 1 |
| Peripheral Arterial Disease | 1 |
| Essential Hypertension | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Ceiling and roofing repair and companies in the United States](https://specstream.ai/data/businesses/ceiling-and-roofing-repair-and-companies/united-states)
- [B2B oil and gas equipment companies in the United States](https://specstream.ai/data/businesses/b2b-oil-and-gas-equipment-companies/united-states)
- [Wholesale grocers in the United States](https://specstream.ai/data/businesses/wholesale-grocers/united-states)
- [Syrian restaurants in the United States](https://specstream.ai/data/businesses/syrian-restaurants/united-states)
- [Rail services in the United States](https://specstream.ai/data/businesses/rail-services/united-states)
- [Packing services in the United States](https://specstream.ai/data/businesses/packing-services/united-states)
